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The important role of the ARF protein in tumor sup-
pression mechanisms is now well established, thanks
to the work of many laboratories over the last eight
years, using molecular and cell biology approaches,
as well as animal model studies, and genetic analysis
of human tumors. This subject has been covered by a
number of excellent reviews1-3. Here, we will summa-
rise the current knowledge on the role of ARF in tu-
mor suppression, highlighting the most recent pro-
gress in the field.
THE BIOLOGY OF ARF
The locus now known as INK4a/ARF first came to
light because of its capacity to encode the cell-cycle
inhibitor, and tumor suppressor protein p16INK4a4,5.
The existence of a second “alternative” transcript
from the locus, originating from an independent first
exon, was described a short time later6-8. However, for
some time, it was unclear whether this transcript en-
coded a peptide and if so, which could be its biologi-
cal relevance. The answer to this uncertainty came a
few months later, with the work from the laboratory
of Charles Sherr9. They first demonstrated the exis-
tence of a second protein product from the locus and
established the capacity of this novel protein to res-
train cell-cycle progression. They also gave ARF its
name, after Alternative Reading Frame, based in the
fact that the two products of the locus, p16INK4a and
ARF, originate from transcripts that share some of
their sequences, but are translated using different re-
ading frames (fig. 1). As a consequence, the amino-
acid sequences of these two proteins are totally unre-
lated. The ARF proteins of human and murine origin
have been designated p14ARF and p19ARF, respecti-
vely, due to their different molecular size9,10. From
the early reports, it was evident that ARF´s action re-
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La proteína ARF en supresión tumoral:
lecciones de modelos animales y tumores
humanos
La proteína ARF es un mediador clave en la activa-
ción del supresor tumoral p53, en respuesta a señales
mitogénicas inapropiadas. ARF está codificada en el
locus INK4a/ARF, junto al regulador de ciclo celular
p16INK4a. Ratones genéticamente deficientes para
ARF presentan una clara predisposición a la forma-
ción de tumores, lo que indica un importante papel
de ARF en protección tumoral. Las alteraciones en el
locus INK4a/ARF son un fenómeno frecuente en tu-
mores humanos. En algunos casos, estas alteraciones
en el locus se traducen en la inactivación específica
de ARF. En esta revisión se resume el conocimiento
actual sobre la funcion biológica y la regulación de
ARF y se comentan las evidencias, procedentes de
estudios con animales modificados genéticamente o
de tumores humanos, que indican un papel relevan-
te de ARF en supresión tumoral.
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quired the presence of functional p5311, suggesting
that ARF was connected to the tumor suppressor
pathway controlled by p53. The molecular nature of
this connection was unveiled soon after, when seve-
ral labs reported the direct interaction of ARF with
the oncogene Mdm2, a transcriptional target of p53
that controls the stability of the p53 protein10,12-14.
The tumour suppressor p53 plays a central role in a
cellular network that responds to a variety of altera-
tions in cell homeostasis which are potentially onco-
genic, such as DNA damage, hypoxia, or telomere
dysfunction, among many others15. Mdm2 is the main
responsible for the transient character of p53 activa-
tion in response to these stress signals16. ARF partici-
pates specifically in the activation of p53 in response
to a long list of stimuli which have in common the
triggering of untimely or excessive mitogenic signals
(fig. 2). Thus, the ARF protein is essential for the anti-
proliferative response of primary cells to the activa-
ted Ras oncogene17, the proapoptotic responses indu-
ced by the viral oncoprotein E1A18 or the Myc
oncogene19, or the limited proliferative potential of
some primary cells in culture19, among others (revie-
wed in references 1 and 2). The picture that has
emerged is that ARF plays a pivotal role in the activa-
tion of p53 in response to a variety of inappropriate
mitogenic stimuli, such as oncogene activation, or
growth under suboptimal conditions, usually desig-
nated as “oncogenic stimuli”1. The levels of the ARF
protein are extremely low in unstressed normal cells.
When cells are exposed to one of the above-described
stimuli, the ARF protein accumulates, locating prefe-
rentially in the nucleoli. This is generally accompa-
nied by a parallel accumulation of Mdm2 in nucleoli,
thereby disrupting the inhibitory interaction between
Mdm2 and p53. The final result of this series of
events, and probably others less well known, is the
accumulation of transcriptionally active p53 in the
nucleus, and the induction of specific responses such
as cell-cycle arrest, or apoptosis. This scheme is un-
doubtedly simplistic and there are accumulating evi-
dences suggesting alternative and parallel ways of ac-
tion for ARF.
One of the issues subject to debate about ARF´s way
of action is the relevance of the nucleolar location of
ARF and the sequestration of Mdm2. It has been
shown, using several cell types and under several dif-
ferent experimental stimuli, that ARF can activate
p53 without relocating Mdm2 from the nucleoplasm
to the nucleoli20-22. It has been suggested that a frac-
tion of ARF resides outside the nucleolus and there
exerts some ill-defined function to activate p53, pos-
sibly through direct inhibition of p53 degradation by
Mdm2, via the ubiquitin proteasome pathway21. Ne-
vertheless, an appropriate localisation seems to be
important for ARF function. Supporting this view, se-
veral tumor-associated mutations in the INK4a/ARF
locus result in an abnormal subcellular localisation
of ARF, either in nucleoplasm or in cytoplasm23-25,
and a subset of aggressive B-cell lymphomas has be-
en shown to display a characteristic accumulation of
ARF in the nucleoplasm26.
Also in contrast with the early linear model connec-
ting ARF to p53 via Mdm2 is the increasing evidence
showing that ARF has functions that are independent
of p53. Thus, ARF retains its ability to induce cell-cy-
cle arrest in cells lacking Mdm2 and p53, albeit with
reduced efficiency27. Also, mice genetically null for
p53, Mdm2 and ARF show a spectrum of tumors
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Fig. 1: Structure of the INK4a/ARF locus.
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Fig. 2. Schematic representation of the connection betwe-
en ARF and p53.  ARF is the key mediator of a specific sig-
nalling pathway that links oncogenic stress signals to p53
via Mdm2.  However, ARF can also function independently
of Mdm2 and/or p53 (see text).  A separate ARF-indepen-
dent pathway is responsible for p53 activation in response
to genotoxic stress, via the kinases ATM and ATR.
which is clearly different from that of Mdm2/p53
double knock-out mice27, suggesting that they are not
fully redundant. Finally, the analysis of p53 and ARF
alterations in tumors in mouse models, or in human
tumors28,29 shows that the inactivation of these genes
is not mutually exclusive, suggesting that they are not
necessarily in a linear pathway, and are not fully re-
dundant.
Which are these p53-independent functions, and do
they involve interaction with novel partners? A large
amount of work has been devoted to answering these
questions, leading to the identification of novel ARF-
interacting proteins, including MdmX, a protein rela-
ted to Mdm230; several members of the E2F family of
transcription factors31; and the tumor suppressor
ING1 (Palmero et al, submitted), among others32-35.
However, the biological relevance of these interac-
tions, and their importance for ARF function are not
clear in many cases. Several examples of p53-inde-
pendent functions of ARF have recently been descri-
bed. One of them is the involvement of ARF in trans-
criptional control, not via p53, but through repression
of the NF-kB transcription factor36. Also worth men-
tioning is the observation that ARF can modulate the
synthesis of ribosomes, through the inhibition of the
processing of ribosomal RNA precursors in the nucle-
olus, in a p53-independent manner37. In this way,
ARF would restrain cell proliferation not only by ac-
ting upon the cell-cycle machinery, but also by bloc-
king protein synthesis in the cell. It is now clear that
ARF has cellular functions different from the Mdm2-
mediated stabilisation of p53, but more work is requi-
red to establish the biological relevance of these no-
vel functions of ARF.
UPSTREAM AND DOWNSTREAM OF ARF
The identification of ARF helped define a novel signa-
lling pathway that connects so-called “oncogenic sti-
muli” to p53 activation. This pathway acts indepen-
dently of the ATM/ATR kinase cascade responsible
for the activation of p53 in response to genotoxic
stress (fig. 2). Consistent with this, ARF-deficiency
has little impact in short term responses to DNA da-
mage11. However, some implication of ARF in p53-
mediated response to genotoxic stress has been sug-
gested, including long-term cell-cycle arrest triggered
by genotoxic drugs38, or telomere erosion39. It has al-
so been suggested that ARF participates in p53 activa-
tion and sensitisation to apoptotic stimuli provoked
by integrin signalling in some cell types40.
The understanding of the signalling pathways that
allow ARF to distinguish between the normal mitoge-
nic signals a cell can receive, and inappropriate mito-
genic stimuli due to potentially oncogenic stress is of
obvious importance. ARF levels are controlled prima-
rily at the transcriptional level and several positive
and negative regulators have been identified, inclu-
ding the Bmi polycomb protein41, the Myc
oncogene19, members of the T-box family42, Twist43,
DMP144,45, or E2F146. Despite the identification of
these regulators, a clear picture of how ARF is activa-
ted in response to oncogenic stress is still lacking.
ARF transcriptional regulation appears to be rather
complex, and probably involves the combined action
of some of these transcription factors. This comple-
xity is exemplified by the connections between ARF
and the transcription factors of the E2F family. Enfor-
ced expression of the E2F1 protein provokes an incre-
ase in ARF levels in several cell types in culture21,46.
However, the biological significance of this observa-
tion is unclear. For instance, primary fibroblasts ge-
netically deficient for E2F1, and E2F2 retain normal
ARF activation and function in response to a variety
of stress signals47. Furthermore, in addition to this
putative role as upstream regulators, E2F proteins
might act downstream of ARF in its antiproliferative
action48.
Little is known about the downstream mediators res-
ponsible for the antiproliferative or proapoptotic ef-
fects of ARF. The cell-cycle inhibitor p21CIP1, a di-
rect transcriptional target of p53, seemed a likely
candidate to mediate cell-cycle arrest imposed by
ARF. However, the genetic evidence does not support
this model, since primary fibroblasts deficient for p21
remain sensitive to ARF-mediated cell-cycle arrest49.
As mentioned above, cell-cycle arrest could be partly
mediated by ARF-E2F interactions31,48. Recent gene
expression profiling experiments have led to the
identification of several transcriptional regulators,
whose expression is increased upon ectopic expres-
sion of ARF50. These represent novel candidate
downstream effectors, which could mediate some of
ARF´s biological functions. It remains to be seen how
relevant these gene products are for ARF function in
vivo.
ARF IN MOUSE CANCER MODELS
The most robust evidence linking ARF to tumor sup-
pression has come from the study of genetically engi-
neered mouse models. The availability of genetic tools
that allow specific inactivation of the products of one
particular locus have shed light on the contribution of
each of the products of the INK4a/ARF locus to tumor
protection51,52. Several mouse models have been gene-
rated to inactivate products of the INK4a/ARF locus.
Mice in which p19ARF has been genetically inactiva-
ted, but retain functional p16, have been obtained by
elimination of the ARF-specific exon 1 beta. These
animals are highly prone to tumor formation11,53.
They develop spontaneous tumors of different origins
at a relatively early age, being sarcomas, T-cell lymp-
homas, and squamous cell carcinomas the most pre-
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valent tumors (table 1). They also show an increased
sensitivity to several carcinogenic treatments. Mice
deficient for p16INK4a, and retaining ARF func-
tion54,55; or deficient for both products of the locus56,
have also been generated, allowing to distinguish the
contribution of each protein to murine tumorigenesis.
Two strains of p16-deficient mice have been generated
independently, following different targeting strategies.
In both cases, the mice show only a modest general
predisposition to tumor formation, but show a signifi-
cant predisposition to the appearance of melano-
mas54,55. This is of particular interest, given the evi-
dence linking alterations in the INK4a/ARF locus 
to melanoma in humans (see below). Finally,
INK4a/ARF-deficient mice, deficient for both
p16INK4a and p19ARF, show a clear tumor-prone
phenotype, with a tumor spectrum similar, but not
identical to ARF-null mice56.
The availability of several mice strains carrying diffe-
rent genetic alterations in an ARF-null background
has allowed investigators to study the functional con-
nections of ARF in vivo (table 1). The use of transge-
nic mice expressing the Myc oncogene in B-lymp-
hocytes (Eµ-Myc) has been very fruitful to unravel
ARF tumor suppressor action, in a series of elegant
studies. These mice develop highly aggressive B-cell
lymphomas, but only after a long latency with high
rates of proliferation and apoptosis in the target cells.
A large proportion of the tumors that eventually arise
show alterations in ARF, p53, or Mdm2. Consistent
with this, Eµ-Myc mice which are genetically defi-
cient for ARF or p53 show an accelerated onset of
lymphomas19,57-59. These in vivo experiments ele-
gantly recapitulate the observations from cell-culture
systems, and clearly indicate that the first response of
the cells to the oncogenic stimuli represented by Myc
is mounting an apoptotic response mediated by the
ARF/Mdm2/p53 pathway. The disabling of this path-
way is therefore necessary for the appearance of tu-
mors in this experimental setting.
ARF could also influence tumor formation through
the control of vascularisation. The phenotypic analy-
sis of ARF-deficient mice has revealed a role for ARF
in the control of vascular regression during eye deve-
lopment60, through the control of proliferation of spe-
cialised perivascular tissue. This unexpected function
of ARF has fuelled speculations that ARF loss might
facilitate tumor growth not only by deregulating pro-
liferation or apoptosis of tumor cells, but also by pro-
moting angiogenesis.
ARF IN HUMAN TUMORS
In contrast to the compelling evidence obtained from
mouse models, the importance of ARF inactivation
in human cancer is less clear. The complex structure
of the INK4a/ARF locus has hindered the elucidation
by classical genetic studies of the specific contribu-
tion to human tumorigenesis of each of the products
of the locus. Nevertheless, the overall evidence from
human tumors supports a more relevant role for
p16INK4a in tumor protection in humans (reviewed
in reference 61). Most alterations of the INK4a/ARF
locus in human tumors are large homozygous dele-
tions, and these usually result in elimination of the
entire INK4a/ARF locus, and even other neighbou-
ring loci, with very few exceptions62 (see also be-
low). However, when point mutations are conside-
red, the vast majority affect p16INK4a61. No point
mutations have yet been reported in the ARF-specific
exon 1beta, and those in the common second exon
usually have minor effects on ARF function14,63. So
far, the most prevailing instances of specific inactiva-
tion of ARF in human tumors are the reports of si-
lencing of the ARF promoter by cytosine methylation
(table 2). Silencing of gene expression by de novo
methylation of regulatory regions is a common me-
chanism for tumor suppressor inactivation in
tumors64. ARF promoter methylation has been re-
ported in a sizeable fraction (up to 60% in some tu-
mor types) of human primary tumors, and tumor
cell lines, of different origins65-70. Methylation of the
ARF promoter occurs, in a large proportion of cases,
independently of p16INK4a methylation, indicating
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TABLE 1. Animal models of ARF deficiency
Mouse strain Phenotype Comments References
ARF -/- Tumor predisposition High incidence of sarcomas (50%) 11, 12
and lymphomas (25%)
ARF:Mdm2:p53 -/- Tumor predisposition Wider tumor spectrum than ARF-/-, 27
high incidence of lymphomas (70%)
ARF:ATM -/- Tumor predisposition No effect in DNA-damage defects of ATM-/- mice 12
Eµ-Myc:ARF -/- Lymphoma formation 19, 57, 58, 59
Tyr-Ras:ARF -/- Melanoma formation Frequent concomitant inactivation of p16INK4a 85, 86, 87
that ARF is specifically targeted in some tumors65.
Interestingly, the analysis of the methylation status
of the ARF promoter using DNA present in plasma71,
or other fluids72 has been used as a prognosis mar-
ker for some tumors.
Familial melanoma syndromes are frequently linked
to losses in the 9p21 chromosomal region, where the
human INK4a/ARF locus is located. Around 50% of
familial melanoma cases show linkage to markers in
this region62. Of these, a high percentage present mu-
tations in p16INK4a, indicating the importance of p16
alterations in the genesis of melanoma. However, a
large number of cases do not show specific altera-
tions in p16, and this has been interpreted as an indi-
cation that ARF, or the neighbouring p15INK4b lo-
cus, could also be implicated. Interestingly, several
instances of specific ARF alterations have been asso-
ciated to melanoma (table 2). Germline mutations af-
fecting exclusively the p14ARF-specific exon 1beta
have been described in several cases of familial mela-
noma25,73,74. These include the specific deletion of
exon 1beta, and short insertions and deletions within
exon 1beta. At least in one case, it has been shown
that the mutation gives rise to a non-functional
p14ARF protein25. Also, point mutations linked to me-
lanoma in the common second exon can result in a
functionally impaired ARF protein24. Taken together,
these results suggest that loss of ARF can have a
substantial impact in melanoma predisposition in hu-
mans.
DIFFERENT ROLE OF ARF IN CELLULAR
IMMORTALISATION AND TRANSFORMATION
IN HUMAN AND MOUSE
A possible explanation for the apparently different ro-
le of ARF in tumor suppression in human and mice,
comes from the studies of the role of ARF in immor-
talisation, and sensitivity to transformation by onco-
genes in primary cells in culture75. Normal primary
cells show a limited proliferative potential when
grown under standard laboratory conditions. After a
period of active growth, these cells cease to divide
and reach a non-proliferative state, called cellular se-
nescence76. In mouse embryonic fibroblasts, the ge-
netic disruption of p19ARF, or p53, is sufficient to
allow escape from senescence. These cells are im-
mortal, and can be propagated indefinitely in cultu-
re11. They have also lost their innate antiproliferative
response against oncogenic Ras, and rather become
fully transformed11,17. In contrast, murine p16INK4a-
deficient fibroblasts are not immortal per se, nor per-
missive to transformation by the Ras oncogene54,55.
Human primary cells show a dramatically different
behaviour in this respect75,77. Immortalisation and
transformation of human fibroblasts in culture is un-
der more stringent controls than in mouse cells, and
several independent genetic alterations are required
including, the activation of telomerase, and the inac-
tivation of the p16 and p53 pathways, besides others
less well defined75,77,78. However, the relative impor-
tance of each of these pathways, and the two products
of the INK4a/ARF locus, in human cell immortalisa-
tion and transformation is controversial. Recent stu-
dies using primary cells from melanoma-prone indi-
viduals79-81 suggest that loss of p16INK4a, retaining
ARF and p53 function, facilitates transformation of
human fibroblasts. However, independent studies
using RNA interference rather suggest a more impor-
tant role for the p53 pathway, although co-operation
between both pathways is required for full transfor-
mation82. Interestingly, all studies coincide to rule out
an important role for p14ARF in this setting, even
when p53 is involved. The regulation of ARF is mar-
kedly different in human and murine cells. Some of
the stimuli known to control ARF expression in mou-
se cells fail to do so in human cells. This is the case of
the Ras oncogene, or the accumulation of divisions in
culture79-81,83. Therefore, it would appear that, con-
trary to mouse cells, the protective action of p53
against oncogenic stress in human cells does not in-
volve ARF. How these in vitro observations can be
translated to the behaviour of tumors in living orga-
nisms is still a challenge, but they should be born in
mind for the analysis of genetic alterations of the two
products of the locus in human tumors.
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TABLE 2. Alterations of p14ARF in human cancer
Methylation of p14ARF promoter
Frequent (40%-60%) Glioblastoma68, bladder71, oral SCC94
Moderate (20%-40%) Colorectal65, gastric66, breast70
Mutations in exon 1 beta
Specific deletion of exon 1 beta T-ALL62, familial melanoma73
Short deletion in exon 1 beta Familial melanoma74
Short insertion in exon 1 beta Familial melanoma25
Mutations in exon 2 affecting ARFa
Missense mutations Familial and sporadic melanoma24
a: most of these mutations also impair p16INK4a function.
CO-OPERATION BETWEEN ARF AND
P16INK4a IN TUMOR SUPPRESSION
A further level of complexity arises from the growing
evidence that there is a significant degree of co-ope-
ration between both products of the INK4a/ARF lo-
cus. This is best exemplified in the case of melanoma
formation, both in mice and humans. As mentioned
above, p16INK4a-deficient mice show a modest pre-
disposition to the appearance of melanomas. This
phenotype is exacerbated in animals lacking an enti-
re copy of the locus, and carrying a p16 inactivating
mutation in the remaining allele54. These mice now
show a high incidence of melanomas and other tu-
mor types. Therefore loss of p16 can cooperate with
ARF heterozygosity, giving rise to a wider spectrum
of tumors. Interestingly, this situation in genetically
engineered mice closely resembles the situation in
many human tumors, where one allele of the locus is
deleted and the remaining allele carries inactivating
mutations in p16. This is in agreement with the data
from human tumors, which indicates that melanoma
patients carrying mutations that impair both p16 and
p14ARF function show a poor prognosis84. Other mu-
rine models support important roles both for ARF
and p16INK4a in melanoma. Mice genetically engi-
neered to express the oncogenic form of the Ras on-
cogene in melanocytes (Tyr-Ras) develop melanomas,
when crossed onto a genetic background of defi-
ciency of p16INK4a, p19ARF or both products of the
INK4a/ARF locus85-87 (table 2). Interestingly, animals
individually deficient for each one of the products
show melanoma predisposition, but frequent somatic
inactivation of the remaining product is observed87.
Therefore loss of either of the products facilitates me-
lanoma formation in this transgenic system, and both
products cooperate in melanoma formation. In addi-
tion to this effect on the onset of spontaneous mela-
noma, shared by p16 and p19ARF, the deficiency in
ARF specifically results in an increased susceptibility
to melanoma induced by UV irradiation. This intri-
guing observation could be interpreted in different
ways: it might reflect a role of ARF in the repair of
DNA damage induced by UV radiation, or alternati-
vely, it might be explained if the main target of UV-in-
duced mutations are in the Rb pathway controlled by
p1688.
Similarly, other complex animal models support the
existence of a functional crosstalk between ARF and
the Rb pathway. Loss of ARF strongly accelerates the
appearance of pituitary tumors in mice heterozygous
for the Rb tumor suppressor89. This phenotype is dif-
ferent from that of double Rb/p53-null mice, again
supporting the view that ARF has p53-independent
functions, important for tumor suppression. Also, pri-
mary fibroblasts from animals deficient for the three
Rb-related “pocket proteins”, Rb, p107 and p130,
where the G1-S cell-cycle checkpoint is presumably
abolished, are refractile to the antiproliferative action
of ARF90,91. Finally, mice doubly deficient for
p16INK4a and p53 show an increased predisposition
to tumor formation, consistent with a co-operative ef-
fect in tumorigenesis of the inactivation of the p16/Rb
and the ARF/p53 pathways92.
Recent observations using the above–described Eµ-
Myc mouse model system have raised the possibility
that the two products of the INK4a/ARF locus might
play important roles at different stages of tumor for-
mation and remission after chemotherapy93. As men-
tioned, ARF loss favours the onset of lymphomas in
this setting, whereas p16 status has little effect at this
stage. However, loss of p16 and p53 has a dramatic ef-
fect in the regression of these tumors after chemothe-
rapy. These investigators suggest that exposure to
chemotherapy drugs triggers both an apoptotic res-
ponse, mediated by p53, and an antiproliferative res-
ponse, similar to senescence, where p16 function is
critical. If these observations can be extrapolated to
human tumors, the implication would be that the
concomitant loss of ARF and p16 can have a dramatic
effect in the clinical outcome of tumors, and they sug-
gest that a detailed study of alterations of both pro-
ducts of the INK4a/ARF locus could be important to
predict the response of tumors to therapy.
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